title: Clinical outcome and long-term management of 17 patients with propionic acidaemia.
abstract: A retrospective study was performed on the clinical outcome and long-term treatment of 17 patients with propionic acidaemia diagnosed during the last 20 years in our hospital. The study group consisted of 12 patients with early onset type of disease and 5 patients with late onset. Seven (41%) patients died, five with early onset and two with late onset. The deceased early onset patients had a median survival of 0.4 years while the deceased late onset patients died at the age of 2.8 and 4 years respectively. Median age of the living early onset patients was 5.2 (1-9.25) years, the late onset patients were 4, 7 and 23 years old. Patients were all treated with natural protein restriction and in most cases carnitine and metronidazole were added. The early onset patients were almost all treated with daily home tube feeding. The mean natural protein intake of early onset patients (6.3 +/- 1.5 g/day) was significantly lower than the natural protein intake of late onset patients (17.6 +/- 5.3 g/day). Supplemental protein intake was higher in early onset patients. The general neurological outcome of our study group was satisfactory with a better outcome for early onset patients. As to growth, many patients showed a failure to thrive, this was particularly for height. The strong protein restriction during the first years of life probably contributed to this.
  
  
  CONCLUSIONS
  The prognosis for patients with propionic acidaemia appeared to be satisfactory in terms of survival and outcome characteristics such as neurological and mental development. Despite these results the authors feel that the prognosis and quality of life of these patients might be improved with liver transplantation or possibly somatic gene therapy in the future.
authors.affiliation: Hopital Enfants Malades, Unite de metabolisme, Paris, France.
authors.forename: S B
authors.initials: SB
authors.lastname: van der Meer
authors.forename: F
authors.initials: F
authors.lastname: Poggi
authors.forename: M
authors.initials: M
authors.lastname: Spada
authors.forename: J P
authors.initials: JP
authors.lastname: Bonnefont
authors.forename: H
authors.initials: H
authors.lastname: Ogier
authors.forename: P
authors.initials: P
authors.lastname: Hubert
authors.forename: E
authors.initials: E
authors.lastname: Depondt
authors.forename: D
authors.initials: D
authors.lastname: Rapoport
authors.forename: D
authors.initials: D
authors.lastname: Rabier
authors.forename: C
authors.initials: C
authors.lastname: Charpentier
authors.forename: P
authors.initials: P
authors.lastname: Parvy
authors.forename: J
authors.initials: J
authors.lastname: Bardet
authors.forename: P
authors.initials: P
authors.lastname: Kamoun
authors.forename: J M
authors.initials: JM
authors.lastname: Saudubray
mesh_terms: D000293:Adolescent; D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000097:blood / Q000178:diet therapy* / Q000401:mortality; D002331:Carnitine / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D018753:Diet, Protein-Restricted; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D016331:Parenteral Nutrition, Home; D011422:Propionates / Q000097:blood*; D015996:Survival Rate
chemical_list: D011422:Propionates; D008795:Metronidazole; D002331:Carnitine